Evolus, Inc. (NASDAQ:EOLS) Stock Has Consensus Price Target of $14.50 According to Analysts

Shares of Evolus, Inc. (NASDAQ:EOLS) have been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $14.50.

Several equities analysts have recently weighed in on EOLS shares. Wall Street Zen raised shares of Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evolus in a research note on Friday, September 11th. BTIG Research reiterated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a report on Wednesday, June 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a report on Tuesday, August 25th.

Insider Buying and Selling at Evolus

In other news, insider David Moatazedi sold 105,108 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total value of $950,176.32. Following the completion of the sale, the insider directly owned 499,592 shares in the company, valued at $4,516,311.68. This represents a 17.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Evolus

Institutional investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC acquired a new position in Evolus during the second quarter worth $38,878,026. BlackRock Inc. purchased a new stake in Evolus in the 2nd quarter valued at $33,595,000. Braidwell LP grew its holdings in Evolus by 1.6% in the 2nd quarter. Braidwell LP now owns 3,155,209 shares of the company’s stock valued at $21,897,000 after buying an additional 50,000 shares in the last quarter. Rice Hall James & Associates LLC acquired a new stake in shares of Evolus in the 2nd quarter worth $8,952,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Evolus in the 1st quarter worth $5,289,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Stock Down 1.0%

Shares of Evolus stock traded down $0.07 during trading hours on Tuesday, reaching $7.67. 17,572 shares of the company’s stock were exchanged, compared to its average volume of 999,565. The business has a fifty day moving average of $8.11 and a two-hundred day moving average of $6.68. The company has a market capitalization of $506.93 million, a P/E ratio of -14.77 and a beta of 1.33. Evolus has a 1 year low of $3.86 and a 1 year high of $9.31.

About Evolus

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for healthcare providers and consumers. The company’s portfolio is designed to address facial wrinkles, folds and other signs of aging through injectable aesthetic treatments.

Evolus’ flagship product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved in the United States for the temporary improvement of moderate to severe glabellar lines in adults. The company markets Jeuveau in the United States and sells the product internationally under the Nuceiva brand in certain markets.

The company has expanded beyond neuromodulators with its Evolysse collection of injectable hyaluronic acid dermal fillers, which is intended to address facial volume loss and wrinkles.